Search Results
Your search for The ASCO ,The ASCO matches 21400 pages
Showing 7251 - 7300Enzalutamide Improves Survival vs Standard First-LineTreatment in Hormone-Sensitive Metastatic Prostate Cancer
As reported inThe New England Journal of Medicine by Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of Monash University and Eastern Health in Melbourne, and colleagues, the phase III ENZAMET trial has shown that the androgen receptor inhibitor enzalutamide improved progression-free and overall survival...
Novel Indications and New Drugs for the Treament of Patients With Renal Cell Carcinoma
Pembrolizumab Plus Axitinib: On April 19, 2019, pembrolizumab (Keytruda) was approved for use in combination with the small-molecule tyrosine kinase inhibitor axitinib (Inlyta) for the first-line treatment of patients with advanced renal cell carcinoma. Approval was based on findings in the phase...
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented during the ASCO20 Virtual Scientific Program1 and published as a brief report in JAMA Oncology,2 Praful Ravi, MB, BChir, of the Dana-Farber Cancer Institute, Boston, and colleagues found that rechallenge with immune checkpoint inhibitor therapy was capable of producing...
Addition of Apalutamide to Androgen-Deprivation Therapy in Metastatic Castration-Sensitive Prostate Cancer
As reported in The New England Journal of Medicine by Kim N. Chi, MD, of BC Cancer and Vancouver Prostate Centre, and colleagues, the first analysis of the phase III TITAN trial has shown that the addition of apalutamide to androgen-deprivation therapy improved radiographic progression-free and...
Phase III Study of AR Antagonist in Nonmetastatic Castration-Resistant Prostate Cancer
In the phase III ARAMIS trial reported in The New England Journal of Medicine,1 Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Universite Paris-Sud, Villejuif, France, and colleagues found that the androgen-receptor (AR) antagonist darolutamide significantly prolonged metastasis-free...
Novel Indications and New Drugs for Castration-Resistant or Castrate-Sensitive Prostate Cancer
The past year has witnessed the U.S. Food and Drug Administration (FDA) approval of a number of drugs for treatment of patients with metastatic castrate-resistant prostate cancer or castrate-sensitive prostate cancer. Castrate-Resistant Prostate Cancer Olaparib: On May 19, 2020, olaparib...
Phase II TRITON2 Study in Metastatic Castration-Resistant Prostate Cancer
The single-arm TRITON2 study demonstrated the efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer.1,2 Results from the study (ClinicalTrials.gov identifier NCT02952534) led to the approval of rucaparib in this...
Final Analysis of the ARAMIS Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer
A year ago, initial results from the double-blind, multicenter, randomized phase III ARAMIS clinical trial evaluating the efficacy and safety of darolutamide, a structurally unique androgen-receptor antagonist, in men with nonmetastatic castration-resistant prostate cancer, were published in The...
Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer
In the final overall survival analysis of the phase III PROSPER trial reported at the ASCO20 Virtual Scientific Program1 and published in The New England Journal of Medicine,2 Cora N. Sternberg, MD, and colleagues found that enzalutamide plus androgen-deprivation therapy (ADT) significantly...
Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial
As reported at the ASCO20 Virtual Scientific Program1 and in The New England Journal of Medicine2 by Neal D. Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, South Carolina, and colleagues, the phase III HERO trial showed sustained castrate testosterone levels and lower risk of...
In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial of any PSMA-targeted therapy and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...
Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer
Initial results of the randomized phase II TheraP trial showed that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177–labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic...
Genitourinary Oncology Highlights 2019–2020 Almanac
Over the past year, we have seen significant advances in the treatment of prostate, kidney, and urothelial cancers that will benefit patients now and in the future. We have learned about the final results of important clinical trials across multiple genitourinary cancers disease states leading to...
Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities
Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus...
Kala Visvanathan, MD, on Ovarian Cancer: Lowering Mortality With Lipophilic Statins
Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses her analysis of data from more than 10,000 women with ovarian cancer. The results suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduced ovarian cancer death rates (Abstract ...
ASH Releases New Clinical Practice Guidelines on the Treatment of Older Adults With Newly Diagnosed Acute Myeloid Leukemia
The American Society of Hematology (ASH) has published new guidelines to help older adults with acute myeloid leukemia (AML) and their health-care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice...
UICC Applauds WHO Global Strategy on Eliminating Cervical Cancer as a Public Health Problem
The Union for International Cancer Control (UICC) lauded the adoption of the World Health Organization’s (WHO) global strategy toward eliminating cervical cancer as a public health problem. WHO Member States adopted the strategy alongside other health resolutions as part of the silence procedure...
Update on Detecting and Treating Biologically Diverse Neuroendocrine Tumors
Neuroendocrine tumors are rare malignancies that arise in neuroendocrine cells, which can occur throughout the body but are most commonly found in the gastrointestinal tract, lungs, and pancreas. Although most neuroendocrine tumors are indolent and take years to grow, some are aggressive and grow...
10-Year Study Indicates Pembrolizumab Provides Long-Term Benefits for Patients With Metastatic Melanoma
A new 10-year analysis, led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and recently published in JAMA Oncology,1 provides new insights into an important question: whether BRAF V600E/K–mutation status or ...
Managing the Cost of Cancer Care Can Be Overwhelming
A cancer diagnosis is often overwhelming in and of itself, and adding financial burdens to the mix can sometimes feel unmanageable. Provide your patients with practical guidelines with the Managing the Cost of Cancer Care booklet from ASCO Answers. It covers health insurance benefits, information...
CMS, CMMI Announce Flexibilities for Oncology Practices Impacted by COVID-19
The Centers for Medicare & Medicaid Services (CMS) recently announced flexibilities for clinicians participating in the 2020 Quality Payment Program (QPP) Merit-based Incentive Payment System (MIPS) who have been impacted by the COVID-19 Public Health Emergency (PHE). Affected clinicians may...
ASCO Conducting Open Search for Chief Medical Officer: Express Interest by August 21, 2020
ASCO is conducting an open search for the position of Chief Medical Officer and Executive Vice President, as current Chief Medical Officer Richard L. Schilsky, MD, FACP, FSCT, FASCO, prepares to retire in February 2021. ASCO’s Chief Medical Officer applies medical and scientific knowledge and...
Conquer Cancer Donors Provide Key Resources for Patients and Providers During the COVID-19 Pandemic
Before there was funding, there was a need. “Patients with cancer needed to understand immediately what COVID-19 meant [for] their health. Providers and practices needed guidance on how to offer safe care,” recalled Howard A. Burris III, MD, FACP, FASCO, Chair of the ASCO Board of Directors, of...
ASCO Special Report: Resuming Cancer Care Delivery During the COVID-19 Pandemic
I’m very pleased to be joined by Piyush Srivastava, MD, Past Chair of ASCO’s Clinical Practice Committee. Dr. Srivastava is a practicing gastrointestinal oncologist, Regional Medical Director of the End of Life Options Program, and Director of Outpatient Palliative Care at Kaiser Permanente Walnut...
Having Cancer Has Not Affected Me in Any Negative Way
I have witnessed much sickness and death over my 35-year career as a medical oncologist. During the early years of my career, I had difficulty dealing with the sickness and death I witnessed on a regular basis. As a result, with help from the Hindu scripture of Bhagavad Gita, I have trained my...
Stand Up To Cancer Announces New Research and Education Effort to Improve Care for Underserved Patients With Lung Cancer
Stand Up To Cancer (SU2C) recently announced a $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health-care equity for underserved patients with lung cancer, including Black individuals and those living in rural communities. The disease remains...
New Effort to Address Health Disparities for Black Men
The Prostate Cancer Foundation and Robert F. Smith, Founder, Chairman and Chief Executive Officer (CEO) of Vista Equity Partners, have announced a new effort to reduce deaths from prostate cancer, one of the largest health disparities facing Black men today. “As African American men are at an...
A Health-Care Journalist Explores Breast Cancer in America, Through the Lens of Her Own Diagnosis
Great strides in research and clinical practice have decreased breast cancer mortality rates by more than 35% since 1990, yet about 40,000 American women die of the disease each year. In Radical: The Science, Culture, and History of Breast Cancer in America, health-care journalist Kate Pickert...
Physicians, New Drugs, and Pharma
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved record numbers of new cancer drugs recently. This is extraordinarily good news for physicians, patients, and drug companies, but it raises important questions as to how effective these drugs are, whether...
Florida Cancer Specialists Appoints New Chief Executive Officer
Florida Cancer Specialists and Research Institute (FCS) announced its Chief Financial Officer, Nathan H. Walcker, MBA, has been named Chief Executive Officer (CEO). Mr. Walcker succeeds the current CEO, Brad Prechtl, MBA, who is retiring but will continue to serve as a consultant. Mr. Prechtl has...
Cleveland Clinic Cancer Center Oncologists Earn National Recognition as Institution Expands Staff
Cleveland Clinic Cancer Center recently announced news about the following physicians, including the appointment of four new staff members: Shilpa Gupta, MD, received a 2-year, $573,850 grant from the Department of Defense to study biomarkers of response and resistance to immunotherapy and to apply ...
NCI Funds Studies of Impact of Telehealth and Telemedicine Capacity for Rural Patients Amid COVID-19 Pandemic
The National Cancer Institute (NCI) has awarded the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) a supplemental grant (P30) to study the role of telehealth in delivering cancer care during the COVID-19 pandemic. The project will evaluate the impact of telehealth on health outcomes, patient...
NRG Oncology Biospecimen Bank Awarded NCI Funding for Next 6 Years
The NRG Oncology Biospecimen Bank will be awarded an additional 6 years of funding from the National Cancer Institute (NCI). This grant will provide biospecimen banking support for the NCI National Clinical Trials Network (NCTN) group NRG Oncology. During the peer-review grant-renewal process, the...
A Pioneering Neurosurgeon Shares Hard-Earned Wisdom Gained Along the Road From the Segregated South
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with noted neurosurgeon Keith L. Black, MD, Chair of Cedars-Sinai Medical Center’s Department of Neurosurgery and Director of the Maxine Dunitz Neurosurgical Institute. During his career, Dr. Black has...
Fox Chase Cancer Center Welcomes New Staff Members
Fox Chase Cancer Center has announced the hiring of three new staff members who will begin their work with the cancer center this month. Brandon Bachert, MD, joins the Department of Diagnostic Imaging as Assistant Professor. He comes to Fox Chase from Albert Einstein Healthcare Network, where he...
American Cancer Society and Flatiron Health Announce Recipients of the Real-World Data Impact Award
Three American Cancer Society (ACS) researchers will receive the Real-World Data Impact Award. The joint grant-making program, supported by the ACS and Flatiron Health, seeks to accelerate cancer research and improve treatment and outcomes for patients. The researchers, already funded by the ACS,...
CICERO Software May Enable Detection of Cancer-Causing Gene Fusions
After years of development, engineering, and enhancement, researchers at St. Jude Children’s Research Hospital in Memphis have made available a software system that enables better detection of gene fusions. The system, called CICERO, offers additional insights into cancers as well as new targets...
Translated Tool From NCCN Measures Mental Health ‘Temperature’ of People With Cancer
The National Comprehensive Cancer Network® (NCCN) recently announced that the NCCN Distress Thermometer has been translated into 46 languages. This free resource helps providers worldwide identify and address the multifactorial aspects of distress patients with cancer can experience. The NCCN...
Dr. Jimmie C. Holland’s Research Has Long Underscored the Importance of Caring for the Whole Patient
Jimmie C. Holland, MD, who served as the inaugural Chairman of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center, died on December 24, 2017, at the age of 89. The ASCO Post paid tribute to Dr. Holland in its January 25, 2018, issue. Here, as part of our ...
Highlights of Research in Lymphomas Presented During the EHA25 Virtual Congress
To complement The ASCO Post’s continued coverage of the virtual edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), here are a few abstracts selected from the meeting proceedings focusing on clinical research in Hodgkin and marginal zone lymphomas. Omission of...
Lost in Translation: A Fisherman’s Tale
The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
National Comprehensive Cancer Network Celebrates Its 25th Year
It was February 1996, and the first annual meeting of the National Comprehensive Cancer Network® (NCCN®) was drawing to a close, when Chief Executive Officer (CEO) Bruce R. Ross, MD, invited comments from the floor. An oncologist who had attended at the urging of a friend—somewhat reluctantly—stood ...
Improving Communication Skills for Oncology Clinicians During the COVID Pandemic
Living in the era of COVID-19 has heightened fear and anxiety among patients with cancer. On the one hand, they are at higher risk of serious COVID-related illness. On the other hand, delaying cancer-focused treatment raises concerns of disease progression. This pandemic has led to dramatic...
Mustafa Raoof, MD, MS, Recognized for Pancreatic Cancer Research
Mustafa Raoof, MD, MS, a surgical oncologist and researcher specializing in gastrointestinal cancers at City of Hope, was recently awarded a Pancreatic Cancer Action Network Career Development Award (PanCAN) and a Young Investigator Award from the National Comprehensive Cancer Network® (NCCN). “I’m ...
SABCS Teams With Tigerlily Foundation for #InclusionPledge to Improve Health-Care Equity for Black Women
In the midst of a global pandemic, while the entire country grapples with recent events highlighting systemic racism, national breast cancer patient organizations are committing to an unprecedented health-equity initiative that focuses on diversity and inclusion. As a result, the San Antonio Breast ...
Roswell Park Gynecologic Oncologists Awarded Leadership Roles
Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, announced the promotion of three staff members to leadership positions. “The dedication of this trio of physicians to their patients and Roswell Park’s mission is unmatched,” said Dr. Odunsi, who also...
Expert Point of View: David Sallman, MD
David Sallman, MD, an assistant member of the Malignant Hematology Department of Moffitt Cancer Center and Research Institute, Tampa, Florida, commented on the IMerge and QUAZAR studies for The ASCO Post. As background, he noted the “predominant struggle” of patients with lower-risk myelodysplastic ...
Edward Chu, MD, MMS, to Lead Cancer Medicine at Albert Einstein College of Medicine and Montefiore Health System
Albert Einstein College of Medicine and Montefiore Health System recently announced that Edward Chu, MD, MMS, has been named Director of the National Cancer Institute-designated Albert Einstein Cancer Center, Vice President for Cancer Medicine at Montefiore Medicine, Professor of Medicine and of...
Huntsman Cancer Institute Brings Home Cancer Care to Rural Utah
A $4.5 million gift from the Huntsman family will fund the expansion of a unique program at Huntsman Cancer Institute (HCI) at the University of Utah that brings specialty cancer care directly to patients in their homes. With this gift, HCI’s Huntsman at Home will extend to rural Utah. The goal is...
